1445 related articles for article (PubMed ID: 29126881)
21. PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer.
Zhu H; Du C; Yuan M; Fu P; He Q; Yang B; Cao J
Drug Discov Today; 2020 Sep; 25(9):1762-1771. PubMed ID: 32663441
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC).
Wein L; Loi S
Breast; 2017 Aug; 34 Suppl 1():S27-S30. PubMed ID: 28668293
[TBL] [Abstract][Full Text] [Related]
23. [Expression of PD-1/PD-L1 in triple-negative breast carcinoma and its significance].
Zhang W; Xu GX; Li JJ; Liu X; Chen YJ; Zhang F
Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):20-24. PubMed ID: 28072971
[No Abstract] [Full Text] [Related]
24. Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.
Brockwell NK; Owen KL; Zanker D; Spurling A; Rautela J; Duivenvoorden HM; Baschuk N; Caramia F; Loi S; Darcy PK; Lim E; Parker BS
Cancer Immunol Res; 2017 Oct; 5(10):871-884. PubMed ID: 28848054
[TBL] [Abstract][Full Text] [Related]
25. Cordyceps militaris polysaccharide converts immunosuppressive macrophages into M1-like phenotype and activates T lymphocytes by inhibiting the PD-L1/PD-1 axis between TAMs and T lymphocytes.
Bi S; Huang W; Chen S; Huang C; Li C; Guo Z; Yang J; Zhu J; Song L; Yu R
Int J Biol Macromol; 2020 May; 150():261-280. PubMed ID: 32044366
[TBL] [Abstract][Full Text] [Related]
26. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
27. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
28. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1.
Roux C; Jafari SM; Shinde R; Duncan G; Cescon DW; Silvester J; Chu MF; Hodgson K; Berger T; Wakeham A; Palomero L; Garcia-Valero M; Pujana MA; Mak TW; McGaha TL; Cappello P; Gorrini C
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4326-4335. PubMed ID: 30770442
[TBL] [Abstract][Full Text] [Related]
29. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
30. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.
Qiu Y; Yang Y; Yang R; Liu C; Hsu JM; Jiang Z; Sun L; Wei Y; Li CW; Yu D; Zhang J; Hung MC
Oncogene; 2021 Aug; 40(31):4992-5001. PubMed ID: 34172932
[TBL] [Abstract][Full Text] [Related]
31. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
[TBL] [Abstract][Full Text] [Related]
32. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
Stovgaard ES; Nielsen D; Hogdall E; Balslev E
Acta Oncol; 2018 Jan; 57(1):74-82. PubMed ID: 29168430
[TBL] [Abstract][Full Text] [Related]
33. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
34. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ
Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
36. MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors.
Dusenbery AC; Maniaci JL; Hillerson ND; Dill EA; Bullock TN; Mills AM
Am J Surg Pathol; 2021 May; 45(5):701-707. PubMed ID: 33739790
[TBL] [Abstract][Full Text] [Related]
37. PD-1/PD-L1 axis importance and tumor microenvironment immune cells.
Lotfinejad P; Kazemi T; Mokhtarzadeh A; Shanehbandi D; Jadidi Niaragh F; Safaei S; Asadi M; Baradaran B
Life Sci; 2020 Oct; 259():118297. PubMed ID: 32822718
[TBL] [Abstract][Full Text] [Related]
38. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
39. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
40. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
